ReviewBlood advances2025
Blinatumomab use in pediatric B-ALL: where are we now?
Review in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- Off-label prescribing in pediatrics: between regulatory gaps and clinical evidence.Italian journal of pediatrics · 2026Article
- Toxicity during induction of pulsed versus continuous prednisolone in children with acute lymphoblastic leukaemia: a multi-centre, open label, randomised, phase 3 trial from India (2016-2022).The Lancet regional health. Southeast Asia · 2026Article
- Blinatumomab bypasses CD28 blockade to sustain T-cell cytotoxicity and improve survival in a xenograft B-ALL model.Journal for immunotherapy of cancer · 2026Article
- Review
- Case Report: Safety and efficacy of blinatumomab in combination with donor lymphocyte infusion for the prophylaxis of relapse following allogeneic hematopoietic stem cell transplantation in a pediatric patient with acute lymphoblastic leukemia.Frontiers in immunology · 2026Article
- Rare but not forgotten: Therapeutic advancements for rare childhood cancers.Molecular therapy. Oncology · 2025Review
- Cancer-related fatigue in children during treatment: a 5-year cohort study of daily patient-reported outcomes with clinical implications.EClinicalMedicine · 2025Article
- Landscape assessment to characterize baseline access and multilevel barriers to IMProve Access to CAR-T CD19 therapy (IMPACT study) across Europe.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBlinatumomab, a bispecific T-cell-engager antibody construct targeting CD19, has emerged as a transformative therapy in B-cell acute lymphoblastic leukemia (B-ALL) in both adult and pediatric populations. In pediatric populations, blinatumomab has demonstrated efficacy both in patients with relapsed or refractory disease and as a component of frontline therapy for newly diagnosed patients. In this review, we discuss the trials that led to regulatory approvals of blinatumomab, with an emphasis on its application in pediatric patients. We will also examine the use of blinatumomab in special populations, explore ongoing questions surrounding its role in the treatment of B-ALL, and highlight key considerations for future clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.